← Back to Search
Novel Targeted System To Deliver Chemotherapeutic Drugs To EphA2-expressing Cancer Cells.
S. Wang, W. J. Placzek, J. Stebbins, Sayantan Mitra, R. Noberini, Mitchell Koolpe, Z. Zhang, R. Dahl, E. Pasquale, M. Pellecchia
Published 2012 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects. We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors. Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel. We found that the peptide-drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site. We believe these studies open the way to the development of a new class of therapeutic compounds that exploit the EphA2 receptor for drug delivery to cancer cells.
This paper references
The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
J. Wykosky (2008)
Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.
I. Dijkgraaf (2007)
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.
K. Brown (2010)
“Click” Conjugation of Peptide on the Surface of Polymeric Nanoparticles for Targeting Tumor Angiogenesis
Stéphanie Deshayes (2011)
In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents.
J. Newton (2009)
Alkaline phosphatase fusions of ligands or receptors as in situ probes for staining of cells, tissues, and embryos.
J. Flanagan (2000)
Click Chemistry: Diverse Chemical Function from a Few Good Reactions.
H. Kolb (2001)
Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy
H. Wu (2010)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
K. Sugahara (2010)
In vivo tumor cell targeting with "click" nanoparticles.
G. von Maltzahn (2008)
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide
S. Hatakeyama (2011)
An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor*
Mitchell Koolpe (2002)
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
Anne Gangloff (2005)
EphrinA1-EphA2 Signal Induces Compaction and Polarization of Madin-Darby Canine Kidney Cells by Inactivating Ezrin through Negative Regulation of RhoA*
Y. Wakayama (2011)
EphA2 as a target for ovarian cancer therapy
C. Landen (2005)
A conditional feedback loop regulates Ras activity through EphA2.
Madhu Macrae (2005)
Multi-functional polymeric nanoparticles for tumour-targeted drug delivery
Lilian E van Vlerken (2006)
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
D. Jackson (2008)
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
S. Singh (2009)
Targeting tumor vasculature with homing peptides from phage display.
E. Ruoslahti (2000)
Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Sayantan Mitra (2010)
A tumor-homing peptide with a targeting specificity related to lymphatic vessels
P. Laakkonen (2002)
Monoclonal antibodies in cancer.
J. Marx (1982)
Protein therapeutics: a summary and pharmacological classification
B. Leader (2008)
Peptide-functionalized nanogels for targeted siRNA delivery.
W. Blackburn (2009)
Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells.
K. E. Scarberry (2008)
Tumor targeting with a selective gelatinase inhibitor
E. Koivunen (1999)
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice
W. Cai (2007)
Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan.
S. Carlsson (1988)
Tumor vasculature targeting through NGR peptide-based drug delivery systems.
A. Corti (2011)
Differential EphA2 epitope display on normal versus malignant cells.
K. Coffman (2003)
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
E. Pasquale (2010)
New methods of drug delivery.
R. Langer (1990)
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells
J. Wykosky (2007)
Arming antibodies: prospects and challenges for immunoconjugates
A. Wu (2005)
EphA2-dependent molecular targeting therapy for malignant tumors.
Rong Biaoxue (2011)
Recent advances in tumor-targeting anticancer drug conjugates.
Stanislav Jaracz (2005)
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
R. Ireton (2005)
TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
W. Yang (2008)
EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts.
K. Miura (2009)
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
W. J. Placzek (2010)
From combinatorial chemistry to cancer-targeting peptides.
Olulanu H. Aina (2007)
Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy.
Jeffry J Cutrera (2011)
High-affinity peptide ligands to prostate-specific antigen identified by polysome selection.
G. Gersuk (1997)
Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
Yongjin Liu (2011)
Antibody targeted drugs as cancer therapeutics
D. Schrama (2006)
Emerging strategies for EphA2 receptor targeting for cancer therapeutics
M. Tandon (2011)
Hypoxia up‐regulates expression of Eph receptors and ephrins in mouse skin
Meri M Vihanto (2005)
Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines.
B. P. Fox (2006)
Targeting Eph receptors with peptides and small molecules: progress and challenges.
R. Noberini (2012)
Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells.
Xin-lin Sun (2011)
This paper is referenced by
High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting
C. Ullman (2015)
Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy
Y. Gong (2017)
Molecular design and synthesis of self-assembling camptothecin drug amphiphiles
Andrew G. Cheetham (2017)
Secondary nuclear targeting of mesoporous silica nano-particles for cancer-specific drug delivery based on charge inversion
J. Zhao (2016)
Ligand-targeted theranostic nanomedicines against cancer.
V. J. Yao (2016)
The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma.
B. Quinn (2015)
The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures
D. R. Singh (2018)
Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications
R. Hughes (2020)
Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems.
Man Ying (2015)
Targeting EphA2 in cancer
Ta Xiao (2020)
Entwicklung zielgerichteter niedermolekularer zytotoxischer Wirkstoffverbindungen mit DNA‐codierten chemischen Bibliotheken
Nikolaus Krall (2013)
Design, Synthesis and Bioevaluation of an EphA2 Receptor‐Based Targeted Delivery System
E. Barile (2014)
Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway
Y. Wang (2015)
Design, synthesis, biological evaluation, and 3D‐QSAR analysis of podophyllotoxin–dioxazole combination as tubulin targeting anticancer agents
Zizhen Wang (2017)
Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis
M. Bansal (2018)
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
Małgorzata Gajdzis (2020)
Cancer Therapy : Preclinical Targeted Delivery of Paclitaxel to EphA 2-Expressing Cancer Cells
S. Wang (2012)
A bifunctional aptamer for the targeted treatment of brain metastases
Joanna Macdonald (2017)
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate
Ahmed F. Salem (2018)
Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery.
X. Xie (2015)
Eph receptors and ephrins: therapeutic opportunities.
A. Barquilla (2015)
Gemcitabine Integrated Nano-Prodrug Carrier System.
Seren Hamsici (2017)
Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
Ahmed F. Salem (2020)
An Efficient Bioorthogonal Strategy Using CuAAC Click Chemistry for Radiofluorinations of SNEW Peptides and the Role of Copper Depletion
M. Pretze (2013)
Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling
M. Gómez-Soler (2019)
Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.
Riccardo Castelli (2015)
(99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Y. Liu (2014)
Ephrin or not? Six tough questions on Eph targeting
C. Giorgio (2020)
Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2.
M. Pretze (2014)
Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.
K. Patel (2016)
Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer
K. Rhoda (2015)
Correction: Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting
J. Kim (2018)See more